Project Grant R21AG089267
Award Date
9/1/24
Completion Date
6/30/26
Dollars Obligated
$661K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $1,550,462 to support a 5-year cross-sectional, longitudinal, and observational study investigating the impact of Alzheimer's disease (AD) risk genes, with a focus on APOE E4, on brain function in older Black/African American individuals living with HIV. The project aims to enroll 120 participants with HIV (60 with and 60 without the APOE E4 allele) and 80 demographically...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $431,750 to Arizona State University (ASU) to investigate the mechanisms by which a specific genetic variant in the apolipoprotein E (APOE) gene, APOE R145C, increases the risk of Alzheimer's disease (AD) among individuals of African ancestry. The research will utilize ASU's expertise in stem cell bioengineering, neurodegenerative disease modeling, and genome editing to generate human...
This National Institute on Aging (NIA) Project Grant award (CFDA 93.866 - Aging Research) for $124,786 provides funding to The Regents of the University of California, San Francisco (UCSF) to conduct research aimed at determining the genetic drivers of ancestry-specific differential penetrance of the APOE4 isoform in sporadic Alzheimer's disease. The key objectives of this 2.5-year project are to: 1) Functionally prioritize a comprehensive set of 10,661 analytically-nominated variants in the...
This Cooperative Agreement award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,406,967.00 in funding to Trustees of Boston University, doing business as Boston University Medical Campus, to conduct research on the effects of APOE genotype on Alzheimer's disease (AD) risk and mechanisms. The key objectives are to: 1) Identify new APOE ε2- and ε4-mediated AD associations using large multi-ethnic genome-wide association study (GWAS) and sequencing datasets, 2)...
This Project Grant award of $431,750 from the National Institute on Aging's Aging Research program (CFDA 93.866) will support research to investigate the interaction between biological sex and APOE genotype in modulating Alzheimer's disease (AD) risk. The research will leverage human induced pluripotent stem cell lines with various APOE genotypes and sex chromosome complements to examine how APOE and sex influence amyloid-beta processing, tau hyperphosphorylation, and transcriptional changes...
This $5,274,018 project grant from the National Institute on Aging, part of the Department of Health and Human Services, supports research under the Aging Research program (CFDA 93.866). The J. David Gladstone Institutes will study the susceptibility and resistance to the detrimental effects of the Apolipoprotein E4 (APOE4) genetic risk factor for Alzheimer's disease. The research aims to characterize neurophysiological, behavioral, and neuropathological differences between new APOE4 mouse lines...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $445,500 to the University of Cincinnati to investigate how the sickle cell trait (SCT) and the apolipoprotein E4 (APOE E4) risk allele interact to impact brain structure, lipidomics, neuroinflammation, and cognitive deficits among older African Americans. The 2-year project aims to elucidate the mechanisms by which SCT modifies the effects of APOE E4 on Alzheimer's disease and related dementias...
This Project Grant award of $751,442 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to optimize and preclinically evaluate a brain-permeable CRISPR-based therapy to edit the APOE4 gene and convert it to the benign APOE3 variant in Alzheimer's disease (AD) models. The key products and services to be delivered include: Optimizing the CRISPR delivery platform using microfluidic synthetic exosomes (SE) to enhance plasma half-life and blood-brain barrier...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a comprehensive study of APOE and the noncoding RNA AANCR to advance Alzheimer's disease treatment. The $1,950,773 award, effective September 30, 2024 through June 30, 2029, will be used by Brown University to elucidate how AANCR regulates APOE transcription and how AANCR itself is modulated to maintain cell-type specific and stress-induced APOE expression. The research will also assess...
This $1,505,109 Project Grant awarded by the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to identify undiagnosed Alzheimer's disease (AD) in non-Hispanic White, Hispanic/Latino, and non-Hispanic African American populations. The project will leverage electronic health records and genetic data to develop disease trajectory models and polygenic risk scores to detect undiagnosed AD, while addressing the issue of underdiagnosis in underserved...